Document:

EX-10.1

EXHIBIT 10.1

XENONICS HOLDINGS, INC.

SECURITIES PURCHASE AND SECURITY AGREEMENT

This Securities Purchase and Security Agreement (the “Agreement”) is made and entered into as
of April 13, 2006 between Xenonics Holdings, Inc., a Nevada corporation (“Xenonics”), and The
Norman Patriot LLC (“Investor”). In consideration of the mutual promises, covenants and conditions
hereinafter set forth, the parties hereby agree as follows:

1. Issuance of Units, Common Stock and Warrants.

(a) Subject to the terms and conditions of this Agreement and in exchange for the delivery of
the aggregate purchase price of $1,650,000 specified in Section 2, Xenonics agrees to issue to
Investor 1,000,000 units (“Units”), with each Unit consisting of (i) one share of Xenonics common
stock, par value $0.001 per share (“Common Stock”), (ii) an immediately exercisable “Class A
Warrant” to purchase one-quarter (0.25) share of Common Stock at a purchase price of $2.20 per
share, and (iii) a “Class B Warrant” to purchase one-quarter (0.25) share of Common Stock at a
purchase price of $3.20 per share, provided that the Class B Warrants shall become exercisable only
after all of the Class A Warrants have been fully exercised. As a result of Xenonics’ issuance of
1,000,000 Units pursuant to this Agreement, Xenonics will issue, in the aggregate, (i) 1,000,000
shares (the “1,000,000 Shares”) of Common Stock, (ii) Class A Warrants to purchase 250,000 shares
of Common Stock at a purchase price of $2.20 per share, and (iii) Class B Warrants to purchase
250,000 shares of Common Stock at a purchase price of $3.20 per share. The shares of Common Stock
that are issuable upon exercise of the Class A Warrants and the Class B Warrants are referred to in
this Agreement as “Warrant Shares.” No fractional shares of Common Stock shall be issuable upon
exercise of the Class A Warrants and Class B Warrants, and each warrant shall have a term of five
years and shall be redeemable by Xenonics upon the terms specified in the warrant certificates.

(b) Concurrently with the execution and delivery of this Agreement and in exchange for the
purchase price of $1,650,000 specified in Section 2, Xenonics shall issue (i) one certificate
evidencing the Class A Warrants and (ii) one certificate evidencing the Class B Warrants. Upon
receipt of approval from the American Stock Exchange to issue the 1,000,000 Shares, Xenonics shall
issue one certificate evidencing the 1,000,000 Shares.

(c) Until all principal and accrued interest on the Secured Promissory Note described in
Section 2 have been paid by Investor, Xenonics shall retain custody of the certificates evidencing
the Class A Warrants, the Class B Warrants, the 1,000,000 Shares and all Warrant Shares that are
issued upon Investor’s exercise of the Class A Warrants or the Class B Warrants. Xenonics shall
deliver such certificates to Investor promptly after the full repayment of the Secured Promissory
Note.

2. Delivery of Purchase Price. Concurrently with the execution and delivery of this
Agreement, Investor shall deliver to Xenonics, as consideration for the Units, the 1,000,000
Shares, the Class A Warrants and the Class B Warrants that Xenonics has agreed to issue to
Investor, (i) $1,000,000 in immediately available funds and (ii) a Secured Promissory Note (the
“Note”) in the principal amount of $650,000, with an interest rate of five percent (5%) per annum
and with all principal and accrued interest thereon due and payable on July 13, 2006; provided,
however, that if the Registration Statement (defined in Section 6 hereof) is not effective by June
11, 2006, then the principal and interest under the Note shall not be due until the thirtieth
(30th) day following the effectiveness of the Registration Statement.

3. Security Agreement.

(a) As security for the full and timely payment of all principal and accrued interest payable
under the Note, Investor hereby grants to Xenonics a continuing and first-priority security
interest (the “Security Interest”) in the following (collectively, the “Collateral”): (i) all
right, title and interest of Investor in and to all Units and the 1,000,000 Shares; (ii) all right,
title and interest of Investor in and to the Class A Warrants and Warrant Shares that are issuable
upon exercise of the Class A Warrants; (iii) all right, title and interest of Investor in and to
the Class B Warrants and the Warrant Shares that are issuable upon exercise of the Class B
Warrants; (iv) all cash, stock and other dividends and distributions paid or payable on the
foregoing; and (v) all proceeds from the sale or other transfer of any of the foregoing.

(b) Prior to the payment in full of all principal and accrued interest under the Note,
Investor agrees not to sell (whether voluntarily, involuntarily, by operation of law, by gift or
for consideration) any of the 1,000,000 Shares or the Warrant Shares or any interest therein or any
portion of the Class A Warrants or the Class B Warrants unless the proceeds of any such sale are
applied to the payment of principal and interest under the Note. Any such sale, pledge or other
transfer shall be null and void, and Xenonics shall not be required to transfer on its books any
shares of Common Stock that are the subject of such sale, pledge or other transfer.

(c) Within ten days after receipt of a written request from Xenonics, Investor shall deliver
to Xenonics any financing statements or stock powers that are requested by Xenonics to evidence and
perfect the Security Interest.

(d) Upon the occurrence of an event of default under the Note, Xenonics shall have the
immediate right to take control of all or any part of the Collateral, with or without judicial
process, and without demand of performance, advertisement or notice to Investor, which are
expressly waived by Investor; provided, however, that if any notice is required by law in
connection with the exercise by Xenonics of its rights and remedies, Investor agrees that ten days’
prior written notice is a reasonable time and manner for notice. Furthermore, Xenonics may
exercise all of the other rights and remedies that are provided to it under this Agreement and to a
secured party by applicable law. Xenonics’ rights and remedies shall include, without limitation,
the power (i) to transfer into its name or into the name of its nominee any or all of the
Collateral and thereafter to receive and retain all cash and other dividends, distributions and
payments made on account of the Collateral, and otherwise act with respect thereto as though it
were the absolute owner thereof, and (ii) to sell all or any portion of the Collateral at a public
or private sale at such place and time and at such prices and other terms as Xenonics may
determine. Xenonics and any other purchaser of the Collateral at any such sale shall hold the
purchased Collateral free from any claim or right on the part of Investor, and Investor hereby
waives any right of redemption, stay or appraisal that it might otherwise have under applicable
law. Any Collateral or the proceeds of the Collateral held or realized upon at any time by
Xenonics following an event of default shall be applied in satisfaction of the amount owed under
the Note until all amounts owed under the Note are fully paid, and thereafter any balance shall be
distributed to Investor.

4. Representations, Warranties and Agreements of Investor. Investor hereby represents
and warrants to Xenonics, and agrees with Xenonics, as follows:

(a) Authorization; Enforceability. Investor has all requisite power and authority to
enter into this Agreement and the Note and to perform its obligations thereunder. This Agreement
and the Note have been duly executed and delivered by Investor.

(b) Purchase for Own Account. Investor is acquiring the Units, the 1,000,000 Shares,
the Class A Warrants, the Class B Warrants and the Warrant Shares (if Investor elects to purchase
such shares) solely for its own account, for investment purposes only and not with a view to, or
for resale in connection with, any distribution or public offering of the Units, the 1,000,000
Shares, the Class A Warrants, the Class B Warrants or Warrant Shares within the meaning of the
Securities Act of 1933, as amended (the “Securities Act”). Investor has no present intention to
sell, offer to sell, or otherwise dispose of or distribute the Units, the Class A Warrants or the
Class B Warrants or any of the 1,000,000 Shares or Warrant Shares. Investor will hold the entire
legal and beneficial interest in and to the Units, the Class A Warrants, the Class B Warrants, the
1,000,000 Shares and the Warrant Shares and does not presently intend to divide or share such
interest with any other person.

(c) Restrictions on Transfer. Investor understands and has been advised by Xenonics
that the Units, the 1,000,000 Shares, the Class A Warrants, the Class B Warrants and the Warrant
Shares have not been registered under the Securities Act or applicable state securities laws in
reliance on exemptions from the registration and/or qualification requirements of such laws, and
that consequently none of such securities may be offered, sold or otherwise transferred, and must
be held indefinitely by Investor, unless and until they are registered under the Securities Act and
applicable state securities laws or until exemptions from such registration and qualification
requirements are available. Investor agrees not to sell the Units, the Class A Warrants, the
Class B Warrants or any of the 1,000,000 Shares or the Warrant Shares without registration under
the Securities Act and applicable state securities laws or exemptions therefrom.

(d) Rule 144. Investor has been advised that Rule 144 promulgated under the
Securities Act, which permits certain limited sales of unregistered securities in specified
circumstances, requires that the securities must be held for a minimum of one year after they have
been purchased and paid for before they may be resold under Rule 144.

(e) Legends. Investor understands and agrees that all certificates evidencing the
1,000,000 Shares, the Warrant Shares, the Class A Warrants and the Class B Warrants (and any
securities issued in respect of such securities upon any stock split, stock dividend, merger,
reorganization or recapitalization) will be imprinted with a legend that reads substantially as set
forth below, together with any other legends that, in the opinion of legal counsel to Xenonics, are
required by the Securities Act or by other federal or state securities laws:

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES
LAWS OF ANY STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON
TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS
PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO
REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY
MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN
INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN
OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE
EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT
AND ANY APPLICABLE STATE SECURITIES LAWS.

(f) Stop Transfer Instructions. Investor agrees that, in order to ensure compliance
with and to enforce the restrictions on transfer referred to in this Agreement, Xenonics may refuse
to transfer the 1,000,000 Shares and the Warrant Shares and may issue appropriate “stop transfer”
instructions to its transfer agent.

(g) Suitability and Investment Experience. Investor is an “accredited investor” as
defined in Rule 501 under the Securities Act and has (i) a pre-existing personal and/or business
relationship with Xenonics, or its officers or directors, such that Investor is aware of the
character, business acumen and general business and financial circumstances of such persons and/or
(ii) such knowledge and experience in business and financial matters that Investor is capable of
evaluating the merits and risks of this investment in the Units, the 1,000,000 Shares, the Class A
Warrants, the Class B Warrants and the Warrant Shares and is capable of protecting Investor’s
interests in connection with such investment.

(h) Access to Data. Investor has had an opportunity to discuss Xenonics’ business,
management and financial affairs with Xenonics’ management and has received or has had full access
to all the information it considers necessary to make an informed investment decision with respect
to the Units, the 1,000,000 Shares, the Class A Warrants, the Class B Warrants and the Warrant
Shares.

5. Representations, Warranties and Agreements of Xenonics. Xenonics hereby represents
and warrants to the Investor, and agrees with the Investor, as follows:

(a) Authorization; Enforceability. Xenonics has all requisite power and authority to
enter into this Agreement and to sell and issue the Units, the 1,000,000 Shares, the Warrant
Shares, the Class A Warrants and the Class B Warrants, subject to obtaining the required approval
of the American Stock Exchange. This Agreement and the certificates evidencing the Class A
Warrants and the Class B Warrants have been duly executed and delivered by Xenonics.

(b) Organization and Good Standing. Xenonics is a corporation duly organized and
existing under, and by virtue of, the laws of the State of Nevada and is in good standing under
such laws. Xenonics has requisite corporate power and authority to own and operate its properties
and assets and to carry on its business as presently conducted.

(c) Validity of Shares. The 1,000,000 Shares and the Warrant Shares, when issued in
compliance with the provisions of this Agreement and the Class A Warrants and the Class B Warrants,
will be validly issued, fully paid and nonassessable, and will be free of any liens or
encumbrances, other than any liens or encumbrances created or imposed by Investor’s actions;
provided, however, that such securities will be subject to restrictions on transfer under state and
federal securities laws. The issuance of the 1,000,000 Shares and the Warrant Shares is not
subject to any preemptive rights held by stockholders of Xenonics.

6. Registration Rights.

(a) On or before May 31, 2006, Xenonics shall prepare and file with the Securities and
Exchange Commission (the “SEC”) a registration statement on Form S-3 or other appropriate form (the
“Registration Statement”), including a prospectus to be included in the Registration Statement (the
“Prospectus”), that will register the resale by Investor of the 1,000,000 Shares and the Warrant
Shares. Xenonics shall use its commercially reasonable efforts to have the Registration Statement
declared effective by the SEC as promptly as possible after the date it is filed. Xenonics is
entitled to register for resale pursuant to the Registration Statement securities issued by
Xenonics that are held by persons other than Investor and, pursuant to applicable SEC rules,
Xenonics is entitled to file with the Registration Statement a combined prospectus that covers the
resale of securities that have been registered by Xenonics on other registration statements filed
with the SEC. Xenonics shall not be required to maintain the Registration Statement in effect (i)
as to any shares of Common Stock that Investor is entitled to sell pursuant to the terms of Rule
144(k) under the Securities Act upon the satisfaction of the two-year holding period described in
Rule 144(k) or (ii) as to any shares that have been publicly sold pursuant to the Registration
Statement.

(b) Investor agrees to cooperate in furnishing promptly to Xenonics in writing any information
requested by Xenonics in connection with the preparation, filing, and processing of the
Registration Statement. Xenonics shall furnish to Investor two copies of each Prospectus that is
included in the effective Registration Statement.

(c) Investor agrees not to sell any shares of Common Stock under the Registration Statement
until it has received copies of the Prospectus from Xenonics and confirmation from Xenonics that
the Registration Statement has become effective. Investor agrees to comply with Prospectus
delivery requirements under the Securities Act. Investor shall not (until further notice) effect
sales of the shares of Common Stock covered by the Registration Statement after receipt of
telephonic, faxed or other written notice from Xenonics that such sales must be suspended until
such time as Xenonics has filed with the SEC an amended or supplemented Registration Statement or
Prospectus.

(d) Xenonics shall pay all SEC filing fees, attorneys’ fees, accountants’ fees and other
customary fees that are incurred by Xenonics in connection with the preparation and filing of the
Registration Statement. However, Investor shall be responsible for the payment of all commissions
or other expenses incurred in connection with Investor’s sales of Common Stock and for any fees and
expenses of Investor’s counsel and other advisors.

(e) Xenonics shall indemnify, defend and hold harmless Investor, its permitted assignees,
officers, directors, agents and employees, each person who controls Investor or a permitted
assignee within the meaning of Section 15 of the Securities Act or Section 20 of the Securities
Exchange Act of 1934 (the “Exchange Act”) and the officers, directors, agents and employees of each
such controlling person, and the respective successors, assigns, estate and personal
representatives of each of the foregoing, to the fullest extent permitted by applicable law, from
and against any and all claims, losses, damages, liabilities, penalties, judgments, costs and
expenses (including, without limitation, reasonable attorneys’ fees and expenses) (collectively,
“Losses”), as incurred, arising out of or relating to any untrue or alleged untrue statement of a
material fact contained in the Registration Statement or any Prospectus, as supplemented or
amended, if applicable, or arising out of or relating to any omission or alleged omission of a
material fact required to be stated therein or necessary to make the statements therein (in the
case of any Prospectus or supplement thereto, in the light of the circumstances under which they
were made) not misleading, except (i) to the extent that such untrue statements or omissions are
based upon information regarding Investor furnished in writing to Xenonics by Investor for use in
the Registration Statement, such Prospectus or in any amendment or supplement thereto, or (ii) as a
result of the failure of Investor to deliver a Prospectus, as amended or supplemented, to a
purchaser in connection with an offer or sale (provided that copies of the Prospectus, as amended
or supplemented, have been provided to Investor by Xenonics for delivery to such purchaser). Such
indemnity shall remain in full force and effect regardless of any investigation made by or on
behalf of Investor and shall survive the transfer of any shares of Common Stock by Investor.

(f) Investor and its permitted assignees shall, jointly and severally, indemnify, defend and
hold harmless Xenonics, its directors, officers, agents and employees, each person who controls
Xenonics (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange
Act), and the directors, officers, agents or employees of such controlling persons, and the
respective successors, assigns, estate and personal representatives of each of the foregoing, to
the fullest extent permitted by applicable law, from and against any and all Losses, as incurred,
arising out of or relating to any untrue or alleged untrue statement of a material fact contained
in the Registration Statement or any Prospectus, as supplemented or amended, if applicable, or
arising out of or relating to any omission or alleged omission of a material fact required to be
stated therein or necessary to make the statements therein (in the case of any Prospectus or
supplement thereto, in the light of the circumstances under which they were made) not misleading,
to the extent that such untrue statement or omission is contained in or omitted from any
information so furnished in writing by Investor to Xenonics for inclusion in the Registration
Statement or such Prospectus.

(g) If a claim for indemnification under Section 6(e) or 6(f) is unavailable to an indemnified
party because of a failure or refusal of a governmental authority to enforce such indemnification
in accordance with its terms (by reason of public policy or otherwise), then each indemnifying
party, in lieu of indemnifying such indemnified party, shall contribute to the amount paid or
payable by such indemnified party as a result of such Losses, in such proportion as is appropriate
to reflect the relative fault of the indemnifying party and indemnified party in connection with
the actions, statements or omissions that resulted in such Losses as well as any other relevant
equitable considerations. The relative fault of such indemnifying party and indemnified party shall
be determined by reference to, among other things, whether any action in question, including any
untrue or alleged untrue statement of a material fact or omission or alleged omission of a material
fact, has been taken or made by, or relates to information supplied by, such indemnifying party or
indemnified party, and the parties’ relative intent, knowledge, access to information and
opportunity to correct or prevent such action, statement or omission. The parties agree that it
would not be just and equitable if contribution pursuant to this Section 6(i) were determined by
pro rata allocation or by any other method of allocation that does not take into account the
equitable considerations referred to in the immediately preceding sentences. However, no person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation.

7. Miscellaneous Provisions.

(a) Modification; Waiver. No modification or waiver of any provision of this
Agreement or consent to departure therefrom shall be effective unless executed in writing by the
parties hereto.

(b) Successors and Assigns. Except as otherwise stated herein, all covenants and
agreements of the parties contained in this Agreement shall be binding upon and inure to the
benefit of their respective successors and assigns.

(c) Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of California, excluding that body of law pertaining to conflict of laws
or choice of law.

(d) Counterparts. This Agreement may be executed in two counterparts, each of which
shall be deemed an original but both of which together shall constitute one and the same
instrument.

(e) Entire Agreement. This Agreement constitutes the entire agreement between the
parties with respect to the subject matter hereof and supersedes any and all prior agreements or
understandings, whether oral or written, with respect to such subject matter.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized representatives effective as of the date and year first above written.

	 	 	 
	THE NORMAN PATRIOT LLC	 	XENONICS HOLDINGS, INC.
	By: /s/ Norman Nouskajian

	 	By: /s/ Richard Naughton
	 

	 	 
	Its: Manager

	 	Its: Chief Executive OfficerEX-10.2

Exhibit 10.2

SECURED PROMISSORY NOTE

$650,000.00 April 13, 2006

FOR VALUE RECEIVED, the undersigned, The Norman Patriot LLC (the “Borrower”), promises to pay
to the order of Xenonics Holdings, Inc., a Nevada corporation (the “Company”), at 2236 Rutherford
Road, Suite 123, Carlsbad, California 92008-7297 (or at such other place as the Company may from
time to time designate to the Borrower), in lawful money of the United States, the principal sum of
Six Hundred Fifty Thousand Dollars ($650,000.00), together with accrued interest on the unpaid
principal balance thereof from and after the date of this Promissory Note at the rate of five
percent (5.0%) per annum.

On July 13, 2006, the entire unpaid principal balance of this Promissory Note and all accrued
interest shall be due and payable; provided, however, that in the event the Registration Statement
defined in Section 6 of the Agreement (as defined below) is not effective by June 11, 2006, then
the principal and interest shall be due on the thirtieth day following the effectiveness of the
Registration Statement.

This Promissory Note is given to the Company in connection with the Borrower’s purchase of
shares of the Company’s common stock and Class A and Class B Warrants pursuant to a Securities
Purchase and Security Agreement (the “Agreement”), dated as of April 13, 2006, between the Company
and the Borrower. The payment of this Promissory Note is secured by a pledge of, and security
interest in, all of the shares of the common stock of the Company and warrants that are issuable to
the Borrower under the Agreement. The terms and conditions of such pledge and security interest
are set forth in the Agreement.

Any principal, interest or other amount payable under this Promissory Note that is not paid
when due shall bear interest from and after the date when due until paid in full at the rate of ten
percent (10.0%) per annum (the “Default Rate”). However, nothing in the preceding sentence shall
be interpreted as a waiver or limitation of the Company’s right to compel payment of all amounts
hereunder when due and payable.

If the Borrower is not in default under this Promissory Note, the Borrower shall have the
privilege of prepaying, without penalty or premium, the outstanding principal balance hereof in
whole or in part at any time or from time to time. Any such prepayment must be accompanied by full
payment of all interest then accrued and unpaid on the principal amount being prepaid. All records
of payments received by the Company shall be maintained at the Company’s principal business office,
and such records shall be binding and conclusive upon the Borrower absent manifest error.

The Borrower’s failure to pay when due any principal or accrued interest owed under this
Promissory Note shall constitute an “Event of Default.” Upon the occurrence of an Event of
Default, the Company shall have the right, at its sole option, at any time thereafter, (i) to
declare the entire balance of principal and accrued interest on this Promissory Note to be
immediately due and payable, (ii) to exercise all of its rights as a secured party under the
Agreement, and (iii) to exercise any and all of its other rights and remedies that are provided
under the Agreement and applicable law. All rights and remedies of the Company are cumulative and
concurrent and may be pursued singularly, successively or together, at the sole discretion of the
Company, and whenever and as often as the Company deems necessary or appropriate.

If any attorney is engaged by the Company to enforce or construe any provision of this
Promissory Note or the Agreement as a consequence of the occurrence of an Event of Default, with or
without the filing of any arbitration proceeding or legal action by the Company, then the Borrower
shall pay immediately on demand all attorneys’ fees and other costs and expenses incurred by the
Company in connection therewith, together with interest thereon from the date of such demand until
paid in full at the Default Rate as if such unpaid fees, costs and expenses had been added to the
principal amount of this Promissory Note.

The Borrower waives presentment and demand for payment, notice of dishonor, protest and notice
of protest, notice of default and any and all lack of diligence or delay by the Company in the
collection or enforcement of this Promissory Note. The Company shall not be deemed to have waived
any right or remedy that it has under this Promissory Note, the Agreement or applicable law unless
it has expressly waived the same in writing or unless this Promissory Note or the Agreement
expressly provides a period of time in which the right or remedy must be exercised. The waiver by
the Company of a right or remedy shall not be construed as a waiver of any other right or remedy or
of any subsequent right or remedy of the same kind.

If any provision of this Promissory Note is determined by an arbitrator or a court of
competent jurisdiction to be invalid, illegal or unenforceable, that provision shall be deemed
severed from this Promissory Note, and the validity, legality and enforceability of the remaining
provisions of this Promissory Note shall remain in full force and effect. If the Company ever
receives any interest payment on this Promissory Note in excess of the maximum interest permitted
by applicable law, such excess amount shall, at the Company’s option, be applied to the reduction
of the unpaid principal balance of this Promissory Note or returned to the Borrower. Time is of
the essence with respect to every provision hereof. This Promissory Note shall be governed by the
internal laws of the State of California without giving effect to conflict-of-law principles.

IN WITNESS WHEREOF, the Borrower has executed and delivered this Promissory Note as of the
date first written above.

	 
	 

	The Norman Patriot LLC

	 

	By: /s/ Norman Nouskajian

	 

	Its: Manager

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]